Literature DB >> 26062825

[Prevalence, type of epilepsy and use of antiepileptic drugs in primary care].

Elena Fernández-Suárez1, Rubén Villa-Estébanez, Alberto Garcia-Martinez, José A Fidalgo-González, Ahmad A Zanabili Al-Sibbai, Javier Salas-Puig.   

Abstract

INTRODUCTION: Epilepsy is a disease with great social and economic impact. The prevalence should be used as the most important basis for planning the secondary and tertiary prevention. AIMS: To identify patients with a diagnosis of epilepsy in a primary care center and determine the prevalence, demographic characteristics, type of epileptic syndrome and the use of antiepileptic drugs. PATIENTS AND METHODS: Retrospective cross-sectional descriptive study. Included 196 patients with a diagnosis of epilepsy belonging to a primary care center and review the medical history, studying socio-demographic variables and clinical-pharmacological.
RESULTS: The prevalence of epilepsy: 8.4/1000 inhabitants. Mean age: 50.3 years. Sex: 52.6% men. SCOPE: 79.6% urban. Family history of epilepsy: 14.8%. Type of epilepsy: symptomatic focal stroke (14.3%), idiopathic generalized (13.8%), focal cryptogenic (8.7%), not classified (31.1%). Average age at the beginning of seizures: 31.6 years. Neurological and/or psychiatric comorbidity: 62.8%. Last follow-up: 18.9% without antiepileptic treatment, 56.6% monotherapy and 24.5% polytherapy. Seizure-free: 76.5%. Drugs most frequently prescribed: valproic acid, carbamazepine, phenytoin, lamotrigine, levetiracetam. 78.6% without side effects. Exitus: 4.1%.
CONCLUSIONS: The prevalence of patients with epilepsy was 8.4/1000 inhabitants, most frequent etiology the symptomatic focal stroke. More than half of patients suffered neurological and/or psychiatric comorbidity. At the end of follow-up the great majority were seizure-free without adverse effects of the antiepileptic drug treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26062825

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  3 in total

1.  The primary prevention of epilepsy: A report of the Prevention Task Force of the International League Against Epilepsy.

Authors:  David J Thurman; Charles E Begley; Arturo Carpio; Sandra Helmers; Dale C Hesdorffer; Jie Mu; Kamadore Touré; Karen L Parko; Charles R Newton
Journal:  Epilepsia       Date:  2018-04-10       Impact factor: 5.864

2.  A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.

Authors:  Stefania Chiappini; Fabrizio Schifano
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

3.  Effect of Chronic Administration of 5-(3-chlorophenyl)-4-Hexyl-2,4 -Dihydro-3H-1,2,4-Triazole-3-Thione (TP-315)-A New Anticonvulsant Drug Candidate-On Living Organisms.

Authors:  Anna Makuch-Kocka; Marta Andres-Mach; Mirosław Zagaja; Anna Śmiech; Magdalena Pizoń; Jolanta Flieger; Judyta Cielecka-Piontek; Tomasz Plech
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.